Upon closing of the transaction, a newly formed holding company, NewAmsterdam Pharma Company N.V. (“NewAmsterdam”) will be led by Michael Davidson, M.D., Chief Executive Officer of the Company. NewAmsterdam’s ordinary shares are expected to be listed on Nasdaq under the ticker symbol “NAMS.”

The new funds include Panacea Venture Healthcare Fund II and Panacea Opportunity Fund I, and are backed by a broad mix of global institutional investors, including sovereigns, endowments, foundations, fund-of-funds, corporate investors and family offices.

The only Chinese company featured in the top-tier and prestigious event that attracts ophthalmology innovators from around the world